8.1 Pharmacotherapy of Urinary Tract and Gynecologic Infections

Pharmacotherapy of Urinary Tract and Gynecologic Infections

Urinary tract and gynecologic infections represent some of the most prevalent clinical presentations encountered in both outpatient ambulatory care and acute inpatient hospital practice. Successful management requires a deep understanding of anatomical barriers, pathogen-specific virulence factors, localized pharmacokinetic distribution, and evolving antimicrobial resistance patterns.

---

Diagnostic Classification and Microbiological Landscape

Urinary tract infections (UTIs) are categorized across anatomical (lower vs. upper tract), clinical (uncomplicated vs. complicated), and demographic axes. Distinguishing these syndromes is vital because drug penetration, spectrum of activity, and therapeutic duration differ fundamentally across classifications.

Pathophysiology and Pathogen Virulence

• Ascending Infection Route: The vast majority (> 95%) of UTIs arise via the retrograde ascension of fecal flora from the periurethral space through the urethra into the bladder lumen, with potential ascension up the ureters into the renal pyelocaliceal system.
• Hematogenous Seeding: Rare (< 2% to 3% of cases) and predominantly associated with Staphylococcus aureus bacteremia (producing renal cortical abscesses or perinephric phlegmon), disseminated candidiasis, or Mycobacterium tuberculosis. The recovery of S. aureus in a non-catheterized urine sample warrants immediate blood cultures and prompt echocardiographic evaluation for endovascular infection.
• Uropathogenic Escherichia coli (UPEC): Accounts for 75% to 95% of community-acquired uncomplicated cystitis and pyelonephritis cases. UPEC strains possess specialized chromosomal virulence determinants known as pathogenicity islands (PAIs):
  • Type 1 Pili (FimH adhesin): Mediate D-mannose-sensitive binding to uroplakin Ia and Ib receptors on superficial bladder umbrella cells. This triggers host actin reorganization, bacterial internalization, and the formation of intracellular bacterial communities (IBCs) and quiescent intracellular reservoirs (QIRs) that evade host defenses and drive recurrent cystitis.
  • P Fimbriae (PapG adhesin): Mediate mannose-resistant binding to digalactoside (alpha-D-galactopyranosyl-(1-4)-beta-D-galactopyranoside) cellular receptors present on the renal collecting duct epithelium and vascular parenchyma, directly driving acute pyelonephritis.
  • Toxins: Hemolysin (HlyA) and Cytotoxic Necrotizing Factor 1 (CNF-1) induce pore formation, urothelial cell exfoliation, and deep tissue invasion.
  • Siderophores (Aerobactin, Salmochelin, Enterobactin): High-affinity iron-scavenging molecules that permit bacterial replication within iron-depleted urine.
• Other Prevalent Uropathogens: Staphylococcus saprophyticus (coagulase-negative staphylococcus causing 5% to 15% of acute cystitis in young, sexually active females; binds urothelial fibronectin), Klebsiella pneumoniae, Proteus mirabilis (produces potent urease, which hydrolyzes urea to carbon dioxide and ammonia, elevating urinary pH > 7.5 to 8.0 and precipitating magnesium ammonium phosphate [struvite] and calcium apatite staghorn calculi), Enterococcus faecalis, and Pseudomonas aeruginosa (prevalent in catheterized, instrumented, or nosocomial settings).

---

Acute Uncomplicated Cystitis in Females

Acute uncomplicated cystitis is defined as a symptomatic lower urinary tract infection (dysuria, urinary frequency, urgency, suprapubic tenderness, without systemic signs of fever or costovertebral tenderness) occurring in non-pregnant, premenopausal adult females with anatomically and functionally normal genitourinary tracts.

First-Line Antimicrobial Regimens (2011 IDSA Guidelines)

The Infectious Diseases Society of America (IDSA) guidelines established three preferred first-line empiric agents based on efficacy, minimal collateral damage (ecological disruption of bowel microflora predisposing to resistant colonization or C. difficile infection), and low resistance prevalence:

Second-Line Regimens: Oral Beta-Lactams

When first-line agents cannot be utilized due to allergy, resistance, or intolerability, oral beta-lactams are recommended:

• Amoxicillin-Clavulanate: 500/125 mg PO BID (or 875/125 mg PO BID) for 5 to 7 days.
• Oral Cephalosporins: Cefpodoxime proxetil 100 mg PO BID, Cefdinir 300 mg PO BID, or Cephalexin 500 mg PO TID-QID for 5 to 7 days.
• Clinical Nuance: Oral beta-lactams exhibit lower clinical and microbiological cure rates and higher relapse rates compared to nitrofurantoin and TMP-SMX in randomized trials. This is attributable to rapid urinary clearance without sustained tissue persistence, incomplete eradication of periurethral and rectal colonization, and variable oral bioavailability.
• Contraindicated Beta-Lactams: Ampicillin and amoxicillin monotherapy must NEVER be used empirically for cystitis because community E. coli aminopenicillin resistance exceeds 40% to 50%.

Stewardship Mandate: Fluoroquinolone Sparing in Cystitis

Fluoroquinolones (ciprofloxacin, levofloxacin) possess potent clinical and microbiological efficacy against uropathogens, but they are strictly reserved as second-line or alternative agents for uncomplicated cystitis.

• FDA Black Box Warnings: Fluoroquinolones are associated with disabling, potentially irreversible toxicities: tendonitis and tendon rupture (most commonly Achilles tendon, exacerbated by concurrent systemic corticosteroids), peripheral neuropathy, central nervous system toxicities (seizures, hallucinations, delirium), QT-interval prolongation / torsades de pointes, dysglycemia, and aortic aneurysm rupture/dissection.
• Collateral Damage: Widespread fluoroquinolone use exerts immense selective pressure that accelerates community carriage of fluoroquinolone-resistant Enterobacterales, methicillin-resistant S. aureus (MRSA), and Clostridioides difficile infection.
• IDSA guidelines strongly emphasize reserving fluoroquinolones for invasive infections, specifically pyelonephritis and prostatitis, where their exceptional tissue distribution is clinically required.

Role of Urinary Analgesics

• Phenazopyridine: Azo dye that exerts local analgesic action on urinary tract mucosa, relieving burning, urgency, and dysuria.
• Prescribing Guidance: Administered at 100 to 200 mg PO three times daily after meals for a maximum of 2 days. Prolonged administration masks progressive symptoms of upper tract invasion or therapeutic failure.
• Safety Warnings: Patients must be counseled that phenazopyridine discolors urine to a bright reddish-orange and permanently stains contact lenses and clothing. Caution is warranted in renal impairment and glucose-6-phosphate dehydrogenase (G6PD) deficiency, where accumulation can precipitate acute methemoglobinemia and hemolytic anemia.

---

Acute Uncomplicated Pyelonephritis

Acute uncomplicated pyelonephritis represents an invasive infection of the renal parenchyma and collecting system in individuals without structural or functional urologic abnormalities. Clinical hallmarks include flank pain, costovertebral angle (CVA) tenderness, fever ($> 38^\circ\text{C}$), chills, rigors, nausea, vomiting, and leukocytosis, frequently accompanied by cystitis symptoms.

                           Suspected Acute Uncomplicated Pyelonephritis
                                                │
                    ┌───────────────────────────┴───────────────────────────┐
                    ▼                                                       ▼
          Mild-to-Moderate Symptoms                               Severe Illness / Inability to
          Able to Tolerate Oral Intake                            Tolerate Oral Fluids / Sepsis
                    │                                                       │
        ┌───────────┴───────────┐                                           ▼
        ▼                       ▼                                 Hospitalize for IV Therapy
Local FQ Resistance < 10%   Local FQ Resistance ≥ 10%             • Ceftriaxone 1–2g IV q24h
• Ciprofloxacin 500mg BID    • Ceftriaxone 1g IV loading dose      • Piperacillin-tazobactam
  x 7 days, OR                 (or Aminoglycoside 5–7mg/kg IV)     • Ciprofloxacin 400mg IV q12h
• Levofloxacin 750mg daily     PLUS Ciprofloxacin 500mg BID        • Aminoglycoside ± Ampicillin
  x 5 days                     x 7 days (or Levofloxacin 750mg     Step-down to oral based on
                               daily x 5 days)                     sensitivities when afebrile

Outpatient Empiric Therapy (2011 IDSA Guidelines)

1. Fluoroquinolones (First-Line Preferred):
   • Ciprofloxacin: 500 mg PO twice daily for 7 days (or 1000 mg extended-release PO once daily for 7 days).
   • Levofloxacin: 750 mg PO once daily for 5 days.
   • Conditionality: Fluoroquinolones may be initiated as oral monotherapy ONLY if the local community prevalence of fluoroquinolone resistance among uropathogens is $< 10\%$.
2. Parenteral Loading Dose Mandate:
   • If local fluoroquinolone resistance is $\ge 10\%$, or if the local resistance rate is unknown, IDSA guidelines mandate administering an initial intravenous loading dose of a long-acting parenteral antimicrobial prior to oral therapy:
     • Ceftriaxone: 1 g IV single dose, OR
     • Consolidated Aminoglycoside: Gentamicin or Tobramycin 5 to 7 mg/kg IV single dose.
   • Following the IV dose, the patient transitions to the 5- to 7-day oral fluoroquinolone course.
3. Oral Trimethoprim-Sulfamethoxazole:
   • TMP-SMX 1 DS tablet PO twice daily for 14 days.
   • Appropriate only if the infecting isolate is known to be susceptible to TMP-SMX. If susceptibility is pending, an initial IV dose of ceftriaxone 1 g or an aminoglycoside is required.
4. Oral Beta-Lactams in Pyelonephritis:
   • Oral beta-lactams (e.g., amoxicillin-clavulanate 875/125 mg BID, cefpodoxime 200 mg BID, cefdinir 300 mg BID) demonstrate significantly higher failure rates and relapses in pyelonephritis due to inferior tissue penetration and rapid renal elimination.
   • If an oral beta-lactam is selected:
     • An initial IV loading dose of ceftriaxone 1 g or an aminoglycoside is MANDATORY, regardless of local resistance rates.
     • The duration of oral beta-lactam therapy must be extended to 10 to 14 days (in contrast to 5–7 days for fluoroquinolones).

Inpatient Parenteral Therapy

Hospitalization is indicated for hemodynamic instability, persistent vomiting or inability to tolerate oral hydration, high-grade bacteremia, pregnancy, severe uncontrolled pain, immunosuppression, or suspected nephrolithiasis with obstruction.

• Empiric Parenteral Regimens:
  • Ceftriaxone 1 to 2 g IV once daily.
  • Piperacillin-tazobactam 3.375 to 4.5 g IV every 6 hours (administered as an extended infusion).
  • Ciprofloxacin 400 mg IV every 12 hours or Levofloxacin 750 mg IV every 24 hours.
  • Aminoglycoside (gentamicin or tobramycin 5 mg/kg once daily) with or without ampicillin (1 to 2 g IV every 6 hours to cover enterococci).
  • Carbapenems (ertapenem 1 g IV daily, or meropenem 1 g IV every 8 hours) reserved for patients with severe sepsis and known prior colonizers or high risk for extended-spectrum beta-lactamase (ESBL)-producing pathogens.
• Step-Down Strategy: Patients can safely be transitioned from IV to oral therapy once they are afebrile for 24 to 48 hours, hemodynamically stable, exhibiting symptom improvement, and tolerating oral intake, guided by definitive urine and blood culture AST results.

---

Complicated Urinary Tract Infections and CAUTI

A complicated UTI (cUTI) occurs in the presence of structural, anatomical, or functional abnormalities of the genitourinary tract, or in hosts with underlying medical conditions that impair host defense mechanisms.

Classification of Complicated UTI

Complicated UTIs include infections occurring in:

• Males (any UTI in a biological male is historically classified as complicated due to anatomical length and potential prostatic involvement).
• Patients with indwelling urinary catheters, stents, nephrostomy tubes, or recent urologic instrumentation.
• Anatomical abnormalities: nephrolithiasis, urethral strictures, prostatic hypertrophy, vesicoureteral reflux, neurogenic bladder, or urinary diversions (ileal conduits).
• Metabolic and systemic conditions: poorly controlled diabetes mellitus, renal insufficiency, renal transplantation, neutropenia, or systemic immunosuppressive therapy.
• Pregnancy.

Catheter-Associated Urinary Tract Infection (CAUTI)

Per the 2019/2009 IDSA Guidelines, CAUTI is defined as an infection occurring in a patient with an indwelling urethral, suprapubic, or nephrostomy catheter currently in place or removed within the preceding 48 hours, characterized by:

1. Presence of symptoms referable to the urinary tract (fever, chills, rigors, altered mental status, costovertebral angle tenderness, suprapubic pain, or acute hematuria).
2. Microbiological confirmation: $\ge 10^3\text{ CFU/mL}$ of $\ge 1$ bacterial species in a properly collected catheter urine specimen.

                      Asymptomatic Bacteriuria (ASB) vs. Symptomatic CAUTI
                                               │
               ┌───────────────────────────────┴───────────────────────────────┐
               ▼                                                               ▼
  Positive Urine Culture WITHOUT Symptoms                         Positive Urine Culture WITH Symptoms
  (e.g., cloudy urine, foul odor, pyuria)                         (Fever, CVA tenderness, rigors, sepsis)
               │                                                               │
               ▼                                                               ▼
   Asymptomatic Bacteriuria (ASB)                                   Catheter-Associated UTI (CAUTI)
   • Do NOT treat with antimicrobials!                              • Remove or exchange catheter if ≥ 2 weeks
   • Treatment causes collateral damage and                         • Collect specimen from fresh catheter
     fosters antimicrobial resistance.                              • Empiric antimicrobials tailored to risk
   • Exceptions: Pregnancy and prior to                             • Duration: 7 days (prompt resolution)
     invasive urologic procedures involving                           or 10–14 days (delayed/bacteremia)
     mucosal bleeding.

Catheter Management and Culture Technique

• Catheter Exchange / Removal: If an indwelling catheter has been in place for $\ge 2$ weeks at the onset of CAUTI and remains clinically necessary, the existing catheter must be removed and replaced prior to initiating antimicrobial therapy, or discontinued entirely. Biofilms on old catheter surfaces shield bacteria from antimicrobials, resulting in rapid relapse.
• Specimen Collection: Urine cultures must be aspirated directly from the sampling port of the newly placed catheter using aseptic technique. Urine should never be collected from the drainage bag or from an old, encrusted catheter lumen.

Empiric Regimen Selection and Treatment Duration in cUTI / CAUTI

• Empiric Spectrum: Regimens must provide potent coverage against resistant Enterobacterales (E. coli, Klebsiella, Proteus, Enterobacter), Pseudomonas aeruginosa, and Enterococcus species.
  • Mild-to-moderate outpatient complicated UTI: Oral fluoroquinolones (ciprofloxacin or levofloxacin) if local resistance $< 10\%$, or oral beta-lactams / TMP-SMX once susceptibility is verified.
  • Severe inpatient / nosocomial CAUTI:
    • Cefepime 2 g IV every 8 hours, OR
    • Piperacillin-tazobactam 4.5 g IV every 6 hours (extended infusion), OR
    • Meropenem 1 g IV every 8 hours (if septic shock or known ESBL colonizer), OR
    • Ceftazidime 2 g IV every 8 hours.
    • Add Vancomycin (target AUC/MIC 400–600 mg$\cdot$h/L) or Daptomycin (6–8 mg/kg IV daily) if Enterococcus faecium or MRSA is suspected.
• Treatment Duration:
  • 7 days is recommended for patients whose catheter is removed or replaced and who experience prompt clinical symptom resolution within 48 to 72 hours.
  • 10 to 14 days is required for patients with a delayed clinical response, ongoing bacteremia, persistent structural abnormalities, or extensive renal parenchymal involvement.
  • 5 days of levofloxacin 750 mg daily is acceptable for patients with complicated cystitis experiencing rapid symptom resolution.

---

Prostatitis: Acute vs. Chronic Bacterial Prostatitis

Prostatitis encompasses a spectrum of inflammatory and infectious conditions affecting the prostate gland. Differentiating acute bacterial prostatitis (ABP) from chronic bacterial prostatitis (CBP) is essential due to divergent anatomical barriers, pharmacokinetic penetration, and therapeutic durations.

Comparison of Acute and Chronic Bacterial Prostatitis

Pharmacokinetics of Prostatic Penetration

The blood-prostate barrier consists of the capillary endothelium and the continuous layer of prostatic epithelial cells joined by apical tight junctions (zonula occludens). For an antimicrobial agent to achieve therapeutic, bactericidal concentrations in uninflamed chronic prostatic stroma and secretions, it must satisfy specific physicochemical criteria:

1. High Lipid Solubility: Lipophilic molecules pass directly through epithelial lipid bilayers via passive non-ionic diffusion. Fluoroquinolones, macrolides, and trimethoprim are lipophilic; beta-lactams and aminoglycosides are hydrophilic and polar, resulting in negligible baseline prostatic entry.
2. Basic Dissociation Constant ($\text{p}K_a$): The pH partition hypothesis dictates that basic compounds with a $\text{p}K_a$ close to physiological pH diffuse across lipid membranes in their uncharged form and become protonated (ionized) in the slightly acidic prostatic fluid. This "ion trapping" mechanism concentrates the drug in prostatic tissue. Trimethoprim ($\text{p}K_a \approx 7.3$) concentrates up to 2- to 3-fold higher in prostatic tissue than in serum. Sulfamethoxazole, by contrast, is an acidic compound ($\text{p}K_a \approx 5.6$) that remains ionized in plasma, achieving prostate-to-serum ratios of only 0.1 to 0.2.
3. Low Serum Protein Binding: Only the unbound (free) fraction of drug in plasma can diffuse across the blood-prostate barrier. Fluoroquinolones exhibit low protein binding (ciprofloxacin 20–40%, levofloxacin 30%), whereas ceftriaxone is highly protein-bound (~90–95%), severely restricting free diffusion into uninflamed tissues.

---

Gynecologic and Pelvic Infections

Pelvic Inflammatory Disease (PID)

Pelvic inflammatory disease comprises an acute polymicrobial infectious spectrum of the female upper genital tract, encompassing any combination of endometritis, salpingitis, tubo-ovarian abscess (TOA), and pelvic peritonitis.

Microbiology and Pathogenesis

• Primary Initiating Pathogens: Neisseria gonorrhoeae and Chlamydia trachomatis initiate mucosal destruction, ciliary loss, and epithelial disruption.
• Secondary Opportunistic Invaders: Ascending vaginal flora, including Mycoplasma genitalium, Streptococcus agalactiae (GBS), enteric Gram-negative bacilli (E. coli), and obligate anaerobes (Bacteroides fragilis, Prevotella species, Peptostreptococcus species, and Atopobium vaginae).
• Sequelae of Inadequate Therapy: Tubal scarring, tubal factor infertility (rates reach 12% after one episode, 23% after two, and 54% after three episodes), ectopic pregnancy (increased 6- to 10-fold), and chronic pelvic pain.

CDC STI Treatment Guidelines Regimens for PID

                                    Suspected Pelvic Inflammatory Disease (PID)
                                                         │
                        ┌────────────────────────────────┴────────────────────────────────┐
                        ▼                                                                 ▼
                Outpatient Therapy                                                Inpatient Therapy
        Mild-to-Moderate Presentation                                     Severe Illness, Pregnancy, TOA,
        Able to tolerate oral fluids                                      Inability to exclude appendicitis
                        │                                                                 │
                        ▼                                                                 ▼
        • Ceftriaxone 500mg IM single dose                                • Regimen A: Cefoxitin 2g IV q6h (or
          (1g if weight ≥ 150kg), PLUS                                      Cefotetan 2g IV q12h) + Doxycycline
        • Doxycycline 100mg PO BID x 14 days, PLUS                          100mg IV/PO q12h, OR
        • Metronidazole 500mg PO BID x 14 days                            • Regimen B: Ampicillin-sulbactam 3g IV
                                                                            q6h + Doxycycline 100mg IV/PO q12h, OR
                                                                          • Regimen C: Clindamycin 900mg IV q8h +
                                                                            Gentamicin 2mg/kg load, then 1.5mg/kg q8h
                                                                          Transition to oral Doxycycline + Metronidazole
                                                                          to complete 14 days total course

1. Preferred Outpatient Regimen:
   • Ceftriaxone: 500 mg IM in a single dose (increase to 1 g IM if body weight $\ge 150\text{ kg}$), PLUS
   • Doxycycline: 100 mg orally twice daily for 14 days, PLUS
   • Metronidazole: 500 mg orally twice daily for 14 days.
   • Rationale for Metronidazole: Contemporary randomized clinical trials demonstrate that adding metronidazole to the ceftriaxone/doxycycline backbone significantly reduces cervical and endometrial isolation of anaerobic bacteria, effectively clears concurrent bacterial vaginosis flora, and decreases the incidence of persistent endometritis.
2. Inpatient Parenteral Regimens:
   • Indications for hospitalization: Tubo-ovarian abscess, pregnancy, severe illness (nausea, vomiting, high fever), surgical emergencies cannot be excluded (e.g., acute appendicitis), failure of outpatient oral therapy after 72 hours, or inability to tolerate oral medications.
   • Regimen A: Cefotetan 2 g IV every 12 hours OR Cefoxitin 2 g IV every 6 hours PLUS Doxycycline 100 mg orally or IV every 12 hours.
   • Regimen B: Ampicillin-sulbactam 3 g IV every 6 hours PLUS Doxycycline 100 mg orally or IV every 12 hours.
   • Regimen C (Alternative for severe penicillin allergy): Clindamycin 900 mg IV every 8 hours PLUS Gentamicin loading dose 2 mg/kg IV followed by maintenance 1.5 mg/kg IV every 8 hours (or consolidated once-daily dosing 5 mg/kg IV once daily).
   • Inpatient parenteral therapy can be transitioned to oral doxycycline 100 mg BID plus metronidazole 500 mg BID after 24 to 48 hours of sustained clinical improvement, completing a total duration of 14 days.

Post-Abortal and Postpartum Endometritis

Postpartum endometritis is an ascending polymicrobial infection of the decidua and myometrium, occurring most frequently following cesarean delivery (especially after prolonged labor or prolonged rupture of membranes).

• Microbiology: Polymicrobial mixture of aerobic and anaerobic vaginal organisms: Bacteroides fragilis group, Prevotella bivia, Peptostreptococcus, Group B Streptococcus (S. agalactiae), Enterococcus faecalis, and Escherichia coli.
• Gold-Standard Regimen:
  • Clindamycin: 900 mg IV every 8 hours, PLUS
  • Gentamicin: 1.5 mg/kg IV every 8 hours (or single-daily dosing 5 mg/kg IV once daily).
  • Ampicillin Addition: Ampicillin 2 g IV every 6 hours is added if enterococcal infection is suspected or if the patient exhibits persistent bacteremia/fever after 48 hours.
  • Alternative Regimen: Ampicillin-sulbactam 3 g IV every 6 hours provides comparable monotherapy coverage against anaerobes, enterococci, and beta-lactamase-producing Enterobacterales.
• Duration and Cessation Criteria:
  • Intravenous therapy is continued until the patient is completely afebrile and clinically asymptomatic for 24 to 48 hours, with normal bowel function and resolving uterine tenderness.
  • Outpatient oral antibiotics are unnecessary following successful clinical cure with parenteral therapy; clinical trials demonstrate no reduction in relapse or infectious complications with routine post-discharge oral antimicrobials.